All Oncology News

The phase 2 CP-MGA271-06 trial closed early following an internal review of safety data of enoblituzumab plus retifanlimab or tebotelimab as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

American Oncology Network, LLC is pleased to announce that three research studies co-authored by AON physicians were presented at the American Society of Clinical Oncology 2022 Annual Meeting, held June 3-7, 2022.

Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.

Daniel J. Hausrath, MD, discusses a collaborative effort to produce a podcast for fellows that reviews the fundamentals, core concepts, and important management approaches in the field, as determined by the latest evidence and expert opinion.

Jill Gilbert, MD, urges healthcare providers to undertake the process of visible and courageous support of the truth in the medical field.

Nivolumab alone or in combination with ipilimumab continued to demonstrate sustained clinical benefit as second- and first-line therapy, respectively, in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Thierry André, MD, discusses the results of the phase 1 GARNET study with dostarlimab and the significance of these findings for patients with mismatch repair–deficient/microsatellite instqability–high solid tumors.

The CAR T-cell therapy anbalcabtagene autoleucel generated strong overall response rates in patients with relapsed/refractory large B-cell lymphoma.

Mili Arora, MD, talks about changing the fellowship program at UC Davis, the effect the COVID-19 pandemic has had on her trainees, and the importance of working late nights with her fellows.

The combination of nivolumab and ipilimumab generated a 100% response rate in patients with mismatch repair–deficient colon cancer and a 29% response rate in patients with MMR-proficient disease.

The Rutgers Board of Governors has named Rutgers Cancer Institute of New Jersey Deputy Director Eileen White, PhD, the Board of Governors Professor of Molecular Biology and Biochemistry at the Rutgers School of Arts and Sciences for her contributions to science and leadership in the fields of apoptosis, autophagy and cancer metabolism.

The expansion of technology includes machine learning, which is quickly emerging as a dynamic aid for clinicians in every aspect of cancer care, from diagnosis to treatment decisions.

The addition of belantamab mafodotin-blmf to lenalidomide and dexamethasone generated responses with acceptable safety in patients with newly diagnosed multiple myeloma who were ineligible to undergo autologous stem cell transplant.

The FDA has granted an orphan drug designation to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors.

Digital health solutions have the potential to improve outcomes via remote symptom monitoring, increase patient/physician communication, and improve patient education.

Ben Ho Park, MD, PhD, summarizes exciting data regarding circulating tumor DNA testing, including its ability to determine the benefits of adjuvant chemotherapy, its successful preliminary use in detecting cancer prior to recurrence, and how it may help guide future therapies.

The addition of nivolumab to FOLFOXIRI and bevacizumab resulted in encouraging responses when used as frontline treatment in patients with advanced or metastatic colorectal cancer harboring RAS or BRAF mutations, irrespective of microsatellite status.

Praluzatamab ravtansine achieved a promising overall response rate in patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

The FDA has granted a fast track designation to belzupacap sarotalocan for the treatment of patients with non–muscle invasive bladder cancer, representing the first virus-like drug conjugate candidate therapy from Aura Biosciences, Inc., the drug developer.

Interim findings from part A of the phase 2/3 RINGSIDE trial indicated that the selective oral gamma-secretase inhibitor, AL102, was found to have favorable tolerability and early antitumor activity in patients with desmoid tumors.

The FDA has accepted for review a biologics license application resubmission for toripalimab both in combination and as monotherapy for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, according to an announcement from drug developer Coherus.

Gregory Vidal, MD, PhD, including the evolution of treatment options for HER2-low breast cancer, emerging antibody-drug conjugates in triple-negative disease, and the viability of HER3 as an emerging target in breast cancer

Patient-reported outcomes from the phase 3 SPARED trial showed that despite consistency in global health status, patients experienced worse nausea and appetite loss with dexamethasone-sparing approaches.

Florida Cancer Specialists & Research Institute, LLC held a ribbon-cutting ceremony on June 16, 2022 to celebrate the opening of a new clinical site in Kissimmee, FL.

The FDA has accepted a biologics license application and granted a priority review designation to mosunetuzumab, a potential first-in-class CD20 and CD3 T-cell engaging bispecific antibody, for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.

The role of NTRK gene fusions across multiple cancer types have led investigators to confirm the marker in real-world data analyses.

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

A panel of experts discuss their perspectives on testing and targeted therapy for actionable mutations in non–small cell lung cancer.

Results from a study of individuals living with HIV show treatment of a precancerous condition known high-grade squamous intraepithelial lesions of the anus cuts the risk of developing anal cancer in this population by more than half.